Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

Molecular Oncology

Volumn 6, Issue 5, 2012, Pages 530-541

  Sorolla, Anabel ^a   Yeramian, Andrée ^a   Valls, Joan ^b   Dolcet, Xavier ^a   Bergadà, Laura ^a   Llombart Cussac, Antoni ^a   Martí, Rosa Maria ^a   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Bortezomib; Endometrial carcinoma; NF B; Sunitinib; Synergy

Indexed keywords

BORTEZOMIB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SHORT HAIRPIN RNA; SUNITINIB; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG POTENTIATION; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; LENTIVIRINAE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84866026922     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.06.006     Document Type: Article

References (49)

1. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
2. Amiri K.I., Horton L.W., LaFleur B.J., Sosman J.A., Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 2004, 64:4912-4918.
3. Atkins M., Jones C.A., Kirkpatrick P. Sunitinib maleate. Nat. Rev. Drug Discov. 2006, 5:279-280.
4. Basu S., Rosenzweig K.R., Youmell M., Price B.D. The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage. Biochem. Biophys. Res. Commun. 1998, 247:79-83.
5. Bauer S., Parry J.A., Muhlenberg T., Brown M.F., Seneviratne D., Chatterjee P., Chin A., Rubin B.P., Kuan S.F., Fletcher J.A., Duensing S., Duensing A. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010, 70:150-159.
6. Bokhman Ia V., Urmancheeva A.F., Neustadt E.L., Kutusheva G.F. Clinical and morphologic diagnosis of uterine sarcoma. Vopr Onkol 1998, 44:175-180.
7. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
8. Chou T.C., Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 1977, 252:6438-6442.
9. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2007, 25:884-896.
10. Dai Y., Rahmani M., Dent P., Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell Biol. 2005, 25:5429-5444.
11. Damaraju V.L., Bouffard D.Y., Wong C.K., Clarke M.L., Mackey J.R., Leblond L., Cass C.E., Grey M., Gourdeau H. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 2007, 7:121.
12. Dizon D.S. Treatment options for advanced endometrial carcinoma. Gynecol. Oncol. 2010, 117:373-381.
13. Dolcet X., Llobet D., Encinas M., Pallares J., Cabero A., Schoenenberger J.A., Comella J.X., Matias-Guiu X. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J. Biol. Chem. 2006, 281:22118-22130.
14. Dritschilo A. Radiosensitivity and transcription factor NF-kappaB inhibition-progress and pitfalls. J. Natl. Cancer Inst. 1999, 91:1910-1911.
15. Elmore L.W., Domson K., Moore J.R., Kornstein M., Burks R.T. Expression of c-kit (CD117) in benign and malignant human endometrial epithelium. Arch. Pathol. Lab. Med. 2001, 125:146-151.
16. Fernández Y., Verhaegen M., Miller T.P., Rush J.L., Steiner P., Opipari A.W., Lowe S.W., Soengas M.S. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 2005, 65:6294-6304.
17. Goel A., Dispenzieri A., Geyer S.M., Greiner S., Peng K.W., Russell S.J. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 2006, 107:4063-4070.
18. Guidi A.J., Abu-Jawdeh G., Tognazzi K., Dvorak H.F., Brown L.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996, 78:454-460.
19. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., Mitsiades C., Munshi N.C., Richardson P.G., Carrasco R.D., Anderson K.C. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
20. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61:3071-3076.
21. Hu Z., Pan X.F., Wu F.Q., Ma L.Y., Liu D.P., Liu Y., Feng T.T., Meng F.Y., Liu X.L., Jiang Q.L., Chen X.Q., Liu J.L., Liu P., Chen Z., Chen S.J., Zhou G.B. Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One 2009, 4:e6257.
22. Ikezoe T., Nishioka C., Tasaka T., Yang Y., Komatsu N., Togitani K., Koeffler H.P., Taguchi H. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol. Cancer Ther. 2006, 5:2522-2530.
23. Ikezoe T., Yang Y., Nishioka C., Bandobashi K., Nakatani H., Taguchi T., Koeffler H.P., Taguchi H. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci. 2006, 97:945-951.
24. Inoue M., Kyo S., Fujita M., Enomoto T., Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994, 54:3049-3053.
25. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
26. Jeong W.J., Mo J.H., Park M.W., Choi I.J., An S.Y., Jeon E.H., Ahn S.H. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol. Ther. 2011, 12:458-465.
27. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310.
28. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstet. Gynecol. Scand. 1984, 63:441-450.
29. Lovecchio J.L., Averette H.E., Lichtinger M., Townsend P.A., Girtanner R.W., Fenton A.N. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum, and megestrol acetate. Obstet. Gynecol. 1984, 63:557-560.
30. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
31. Miller S.C., Huang R., Sakamuru S., Shukla S.J., Attene-Ramos M.S., Shinn P., Van Leer D., Leister W., Austin C.P., Xia M. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem. Pharmacol. 2010, 79:1272-1280.
32. Munshi A., Kurland J.F., Nishikawa T., Chiao P.J., Andreeff M., Meyn R.E. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol. Cancer Ther. 2004, 3:985-992.
33. Nawrocki S.T., Carew J.S., Dunner K., Boise L.H., Chiao P.J., Huang P., Abbruzzese J.L., McConkey D.J. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 2005, 65:11510-11519.
34. Nemeth Z.H., Wong H.R., Odoms K., Deitch E.A., Szabo C., Vizi E.S., Hasko G. Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells. Mol. Pharmacol. 2004, 65:342-349.
35. Niikura H., Sasano H., Matsunaga G., Watanabe K., Ito K., Sato S., Yajima A. Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum. Pathol. 1995, 26:892-896.
36. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., Adams J., Esseltine D.L., Elliott P.J., Pien C.S., Guerciolini R., Anderson J.K., Depcik-Smith N.D., Bhagat R., Lehman M.J., Novick S.C., O'Connor O.A., Soignet S.L. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20:4420-4427.
37. Pallares J., Martinez-Guitarte J.L., Dolcet X., Llobet D., Rue M., Palacios J., Prat J., Matias-Guiu X. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J. Pathol. 2004, 204:569-577.
38. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374:324-339.
39. Scobie J.V., Acs G., Bandera C.A., Blank S.V., Wheeler J.E., Pasha T.L., Salscheider M., Zhang P.J. C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. Int. J. Gynecol. Pathol. 2003, 22:149-155.
40. Singh P.P., Joshi S., Russell P.J., Nair S., Khatri A. Purine nucleoside phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer. BMC Cancer 2011, 11:368.
41. Slomovitz B.M., Broaddus R.R., Schmandt R., Wu W., Oh J.C., Ramondetta L.M., Burke T.W., Gershenson D.M., Lu K.H. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol. Oncol. 2004, 95:32-36.
42. Sosman J.A., Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin. Cancer Res. 2006, 12:2376s-2383s.
43. Tiedemann R.E., Schmidt J., Keats J.J., Shi C.X., Zhu Y.X., Palmer S.E., Mao X., Schimmer A.D., Stewart A.K. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 2009, 113:4027-4037.
44. Wolfson A.H., Sightler S.E., Markoe A.M., Schwade J.G., Averette H.E., Ganjei P., Hilsenbeck S.G. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol. Oncol. 1992, 45:142-146.
45. Wozniak M.B., Villuendas R., Bischoff J.R., Aparicio C.B., Martínez Leal J.F., de La Cueva P., Rodriguez M.E., Herreros B., Martin-Perez D., Longo M.I., Herrera M., Piris M.A., Ortiz-Romero P.L. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 2010, 95:613-621.
46. Yeramian A., Sorolla A., Velasco A., Santacana M., Dolcet X., Valls J., Abal L., Moreno S., Egido R., Casanova J.M., Puig S., Vilella R., Llombart-Cussac A., Matias-Guiu X., Marti R.M. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Int. J. Cancer 2011, 130:967-978.
47. Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M., Emoto M., Sakamoto A., Sakamoto T., Maruyama H., Sato S., Mizunuma H., Smith S.K. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin. Cancer Res. 2003, 9:1361-1369.
48. Yu C., Friday B.B., Lai J.P., Yang L., Sarkaria J., Kay N.E., Carter C.A., Roberts L.R., Kaufmann S.H., Adjei A.A. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 2006, 5:2378-2387.
49. Zhu H., Zhang L., Dong F., Guo W., Wu S., Teraishi F., Davis J.J., Chiao P.J., Fang B. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005, 24:4993-4999.